A deforming birth defect has a devastating psychological impact upon the child s parents, and has the potential for life-long impact upon the physical, psychological and socio-economic well-being of the child.
Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point.